2. Search Result
Search Result
Results for "

Mps1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12862
    Mps1-IN-7

    		Mps1 Cancer
    Mps1-IN-7 is a potent MPS1 inhibitor (IC50 of 0.020 μM) over JNK1 and JNK2 (JNK1 IC50= 0.11 μM, JNK2 IC50=0.22 μM). Mps1-IN-7 inhibit SW620, CAL51, Miapaca-2, RMG1 cell growth with GI50 values of 0.065, 0.068, 0.25, and 0.110 μM,respectively [1].
    Mps1-IN-7
  • HY-13994
    Mps1-IN-2

    		Mps1 Polo-like Kinase (PLK) Cancer
    Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC50 and a Kd of 145 nM and 12 nM for Mps1 and a Kd of 61 nM for Plk1.
    Mps1-IN-2
  • HY-12401
    Mps1-IN-3
    1 Publications Verification

    		 Mps1 Cancer
    Mps1-IN-3 is a potent and selective MPS1 kinase inhibitor, with an IC50 of 50 nM.
    Mps1-IN-3
  • HY-12401A
    Mps1-IN-3 hydrochloride
    1 Publications Verification

    		 Mps1 Cancer
    Mps1-IN-3 hydrochloride is a potent and selective Mps1 inhibitor with an IC50 value of 50 nM. Mps1-IN-3 hydrochloride can inhibit the proliferation of glioblastoma cells, and effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft model [1].
    Mps1-IN-3 hydrochloride
  • HY-13298
    Mps1-IN-1
    3 Publications Verification

    		 Mps1 Cancer
    Mps1-IN-1 is a potent, selective and ATP-competitive Mps1 kinase inhibitor, with an IC50 and a Kd of 367 nM and 27 nM [1].
    Mps1-IN-1
  • HY-160419
    Mps1-IN-8

    		Mps1 Cancer
    Mps1-IN-8 is a Mps1 inhibitor. Mps1-IN-8 can be used in the study of various tumors [1].
    Mps1-IN-8
  • HY-149959
    Mps1-IN-6

    		Mps1 Cancer
    Mps1-IN-6 is a potent Mps1 inhibitor with an IC50 value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity [1].
    Mps1-IN-6
  • HY-151980
    Mps1-IN-5

    		Mps1 Apoptosis Cancer
    Mps1-IN-5 is a potent and orally active Mps1 inhibitor with an IC50 value of 29 nM. Mps1-IN-5 induces Apoptosis and cell cycle arrests at G2/M phase. Mps1-IN-5 shows antiproliferative activity and anti-tumor activity. Mps1-IN-5 inhibits phosphorylation of Mps1 and induces DNA damage [1].
    Mps1-IN-5
  • HY-110347
    Mps1-IN-1 dihydrochloride

    		Mps1 Cancer
    Mps1-IN-1 dihydrochloride is a potent and ATP-competitive Mps1 kinase inhibitor with an IC50 of 367 nM. Mps1-IN-1 dihydrochloride inhibit Mps1 mitotic kinase activity and abrogates spindle assembly checkpoint (SAC) function. Mps1-IN-1 dihydrochloride decreases the viability of both cancer and ‘normal’ cells [1].
    Mps1-IN-1 dihydrochloride
  • HY-12658
    Mps1-IN-4

    		Mps1 Cancer
    Mps1-IN-4 is a selective Monopolar spindle 1 (Mps1) inhibitor with antiproliferative activity for cancer research [1].
    Mps1-IN-4
  • HY-168155
    Mps1-IN-9

    		Others Cancer
    Mps1-IN-9
  • HY-168540
    PROTAC MPS1 degrader 1

    		PROTACs Mps1 Aurora Kinase Cancer
    PROTAC MPS1 degrader 1 (Compound 19) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA and AURKB, with DC50s of 17.7, 108.7 and 570.3 nM, respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168542); Black: linker (HY-W141926); Blue: ligand for E3 ligase (HY-10984) [1].
    PROTAC MPS1 degrader 1
  • HY-168543
    PROTAC MPS1 degrader 2

    		PROTACs Aurora Kinase Mps1 Cancer
    PROTAC MPS1 degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA and AURKB, with DC50s of 42.0, 2.1 and 154.0 nM, respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168545); Black: linker (HY-N0420); Blue: ligand for E3 ligase (HY-10984) [1].
    PROTAC MPS1 degrader 2
  • HY-110115
    TC-Mps1-12

    		Mps1 Cancer
    TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor, with an IC50 of 6.4 nM [1].
    TC-Mps1-12
  • HY-112162
    BOS-172722
    2 Publications Verification

    		 Mps1 Cancer
    BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC50 of 11 nM and 63 nM for MPS1 (1 mM ATP) and P-MPS1, respectively. BOS-172722 also has potential for the study of various forms of breast cancer [1].
    BOS-172722
  • HY-144308
    RMS-07

    		Mps1 Others
    RMS-07 is a covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor, with an apparent IC50 of 13.1 nM. RMS-07 targets a poorly conserved cysteine in the kinase's hinge region [1].
    RMS-07
  • HY-164516
    ONCOII

    		Mps1 Cancer
    ONCOII is an Mps1 inhibitor with an IC50 of 10.8 nM. The inhibitory activity of ONCOII against Mps1 is affected by naturally occurring mutations in the Mps1 gene, and cells with Mps1 mutations exhibit increased resistance to ONCOII. ONCOII can be used in cancer research [1].
    ONCOII
  • HY-14710
    AZ3146
    Maximum Cited Publications
    6 Publications Verification

    		 Mps1 Cancer
    AZ3146 is a reasonably potent Mps1 and TTK inhibitor, with IC50 of 35 nM for Mps1 Cat.
    AZ3146
  • HY-110242
    Mps-BAY2a

    		Mps1 Apoptosis Cancer
    Mps-BAY2a is a monopolar spindle 1 (MPS1) inhibitor with an IC50 of 1 nM against human MPS1. Mps-BAY2a induces mitotic aberrations and apoptosis in cancer cells [1].
    Mps-BAY2a
  • HY-12858
    Empesertib
    3 Publications Verification

    BAY 1161909

    		 Mps1 Cancer
    Empesertib (BAY 1161909) is a potent Mps1 inhibitor, with an IC50 of < 1 nM.
    Empesertib
  • HY-120704
    Mps-BAY2b

    		Mps1 Cancer
    Mps-BAY2b is a oral active monopolar spindle 1 (MPS1) inhibitor with the IC50 of 14 nM (human MPS1). Mps-BAY2b shows anticancer activity and can be used for study of cancer [1].
    Mps-BAY2b
  • HY-164501
    Mps-BAY1

    		Mps1 Apoptosis Cancer
    Mps-BAY1 is an MPS1 inhibitor with anticancer activity. Mps-BAY1 inhibits cell proliferation and induces apoptosis by activating mitotic catastrophe in cancer cells, generating global aneuploidy and polyploidy. Mps-BAY1 can be used in the study of colorectal cancer and cervical cancer [1].
    Mps-BAY1
  • HY-12382
    NMS-P715

    		Mps1 Cancer
    NMS-P715 is a selective, ATP-competitive inhibitor of MPS1, with an IC50 of 182 nM.
    NMS-P715
  • HY-12660
    MPI-0479605
    3 Publications Verification

    		 Mps1 Apoptosis Cancer
    MPI-0479605 is a potent and selective ATP-competitive inhibitor of Mps1, with an IC50 of 1.8 nM.
    MPI-0479605
  • HY-12603
    CCT251455

    		Mps1 Cancer
    CCT251455 is a potent and selective mitotic kinase monopolar spindle 1 (MPS1) inhibitor with an IC50 of 3 nM.
    CCT251455
  • HY-164518
    PF-3837

    		Mps1 Apoptosis Cancer
    PF-3837 is an Mps1 kinase inhibitor with a Ki value of 0.33 nM and an IC50 value of 5.5 nM. PF-3837 interferes with the cell cycle checkpoint by inhibiting Mps1 catalytic activity, reducing genomic stability, thereby inducing cancer cell apoptosis (Apoptosis). PF-3837 can be used in research on breast cancer [1].
    PF-3837
  • HY-12859
    BAY1217389
    5 Publications Verification

    		 Mps1 Cancer
    BAY 1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (MPS1) kinase with an IC50 value less than 10 nM.
    BAY1217389
  • HY-168545
    TTK ligand 3

    		Ligands for Target Protein for PROTAC Mps1 Cancer
    TTK ligand 3 (Compound 5) is a ligand of monopolar spindle 1 (Mps1, TTK) that can be used in the synthesis of PROTAC (HY-168543) [1].
    TTK ligand 3
  • HY-164519
    PF-7006

    		Mps1 Apoptosis Cancer
    PF-7006 is an Mps1 kinase inhibitor with a Ki value of 0.27 nM and an IC50 value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research [1].
    PF-7006
  • HY-101340A
    Luvixasertib hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    CFI-402257 hydrochloride

    		 Mps1 Cancer
    CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity [1].
    Luvixasertib hydrochloride
  • HY-101340
    Luvixasertib
    Maximum Cited Publications
    6 Publications Verification

    CFI-402257

    		 Mps1 Cancer
    CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity [1].
    Luvixasertib
  • HY-123675
    CFI-400936

    		Others Cancer
    CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity [1].
    CFI-400936

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: